Kenvue Inc. (NYSE:KVUE – Get Free Report) saw unusually large options trading on Monday. Traders purchased 17,400 call options on the stock. This represents an increase of 54% compared to the typical volume of 11,333 call options.
Insider Activity
In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.59% of the company’s stock.
Institutional Trading of Kenvue
Several large investors have recently modified their holdings of KVUE. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Kenvue during the 2nd quarter worth $6,528,000. Jump Financial LLC grew its holdings in shares of Kenvue by 210.6% during the 2nd quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after purchasing an additional 37,170 shares in the last quarter. AXA S.A. lifted its position in shares of Kenvue by 21.1% during the 2nd quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after buying an additional 8,524 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after buying an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after buying an additional 10,885 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Kenvue Stock Performance
Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.24 EPS. On average, equities research analysts anticipate that Kenvue will post 1.16 EPS for the current year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date of this dividend is Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.
Analyst Upgrades and Downgrades
KVUE has been the topic of several research reports. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 8th. Barclays cut their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Canaccord Genuity Group boosted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Finally, UBS Group dropped their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and a consensus target price of $19.33.
Get Our Latest Report on Kenvue
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
